Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data
- 20 February 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 54 (3), 439-444
- https://doi.org/10.1016/j.jpba.2010.09.004
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- In Vitro–In Vivo Correlation: Importance of Dissolution in IVIVCDissolution Technologies, 2007
- Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor AmprenavirAntimicrobial Agents and Chemotherapy, 2004
- Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected PatientsAntimicrobial Agents and Chemotherapy, 2004
- Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 2002
- Guidelines on Dissolution Profile ComparisonDrug Information Journal, 2001
- Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlationsJournal of Controlled Release, 2001
- Modeling and comparison of dissolution profilesEuropean Journal of Pharmaceutical Sciences, 2001
- In vitro–in vivo correlations for lipophilic, poorly water-soluble drugsEuropean Journal of Pharmaceutical Sciences, 2000
- Methods to Compare Dissolution ProfilesDrug Information Journal, 1996
- A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo BioavailabilityPharmaceutical Research, 1995